

# Colin Berry

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10994041/publications.pdf>

Version: 2024-02-01

249  
papers

18,658  
citations

13099

68  
h-index

13771

129  
g-index

250  
all docs

250  
docs citations

250  
times ranked

18657  
citing authors

#	ARTICLE	IF	CITATIONS
1	Invasive coronary physiology in patients with angina and non-obstructive coronary artery disease: a consensus document from the coronary microvascular dysfunction workstream of the British Heart Foundation/National Institute for Health Research Partnership. <i>Heart</i> , 2023, 109, 88-95.	2.9	26
2	What Is the Role of Assessing Ischemia to Optimize Therapy and Outcomes for Patients with Stable Angina and Non-obstructed Coronary Arteries?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1027-1038.	2.6	2
3	Intramyocardial Hemorrhage. <i>Journal of the American College of Cardiology</i> , 2022, 79, 49-51.	2.8	5
4	A Noncontrast CMR Risk Score for Long-Term Risk Stratification in Reperfused ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 431-440.	5.3	8
5	Is Platelet Reactivity a Therapeutic Target to Limit Microvascular Obstruction?. <i>Journal of the American Heart Association</i> , 2022, 11, e024930.	3.7	0
6	Coronary Arterial Function and Disease in Women With No Obstructive Coronary Arteries. <i>Circulation Research</i> , 2022, 130, 529-551.	4.5	29
7	Personalizing the Competing Risks for Thrombotic and Bleeding Events in Ischemia With Nonobstructed Coronary Arteries. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 440-442.	2.9	0
8	High-sensitivity cardiac troponin and the diagnosis of myocardial infarction in patients with kidney impairment. <i>Kidney International</i> , 2022, 102, 149-159.	5.2	9
9	Mechanistic study of the effect of Endothelin SNPs in microvascular angina – Protocol of the PRIZE Endothelin Sub-Study. <i>IJC Heart and Vasculature</i> , 2022, 39, 100980.	1.1	2
10	Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, e023207.	3.7	54
11	Validation of the myocardial-ischæmic-injury-index machine learning algorithm to guide the diagnosis of myocardial infarction in a heterogeneous population: a prespecified exploratory analysis. <i>The Lancet Digital Health</i> , 2022, 4, e300-e308.	12.3	18
12	The British Cardiovascular Society and clinical studies in ischaemic heart disease: from RITA to ORBITA, and beyond. <i>Heart</i> , 2022, 108, 800-806.	2.9	0
13	Definition and epidemiology of coronary microvascular disease. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1763-1775.	2.1	15
14	A multisystem, cardio-renal investigation of post-COVID-19 illness. <i>Nature Medicine</i> , 2022, 28, 1303-1313.	30.7	39
15	Phenotype-based management of coronary microvascular dysfunction. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 3332-3340.	2.1	5
16	Rationale and Design for the LOnger-term effects of SARS-CoV-2 INfection on blood Vessels And blood pResure (LOCHINVAR): an observational phenotyping study. <i>Open Heart</i> , 2022, 9, e002057.	2.3	3
17	Coronary physiological assessment in the catheter laboratory: haemodynamics, clinical assessment and future perspectives. <i>Heart</i> , 2022, 108, 1737-1746.	2.9	7
18	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1012-1014.	5.3	5

#	ARTICLE	IF	CITATIONS
19	Assessment of Oxygen Supply-Demand Imbalance and Outcomes Among Patients With Type 2 Myocardial Infarction. <i>JAMA Network Open</i> , 2022, 5, e2220162.	5.9	6
20	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021, 143, 516-525.	1.6	237
21	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 486-495.	4.0	44
22	Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. <i>Cardiovascular Research</i> , 2021, 117, 320-329.	3.8	3
23	Cost-effectiveness of cardiovascular imaging for stable coronary heart disease. <i>Heart</i> , 2021, 107, 381-388.	2.9	12
24	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. <i>Heart</i> , 2021, 107, 299-312.	2.9	6
25	Apparent growth tensor of left ventricular post myocardial infarction "In human first natural history study. <i>Computers in Biology and Medicine</i> , 2021, 129, 104168.	7.0	7
26	Global longitudinal strain by feature-tracking cardiovascular magnetic resonance imaging predicts mortality in patients with end-stage kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2187-2196.	2.9	3
27	Percutaneous coronary intervention and 30-day unplanned readmission with chest pain in the United States (Nationwide Readmissions Database). <i>Clinical Cardiology</i> , 2021, 44, 291-306.	1.8	3
28	Predictors of Microvascular Reperfusion After Myocardial Infarction. <i>Current Cardiology Reports</i> , 2021, 23, 21.	2.9	5
29	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003183.	3.6	7
30	The Health Economics of Ischemia With Nonobstructive Coronary Arteries. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1380-1383.	5.3	2
31	Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. <i>European Heart Journal</i> , 2021, 42, 4592-4600.	2.2	84
32	Cardiovascular Complications Are Uncommon in Healthcare Workers With Mild or Asymptomatic COVID-19 Infection. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2167-2169.	5.3	4
33	Thermodilution-derived temperature recovery time: a novel predictor of microvascular reperfusion and prognosis after myocardial infarction. <i>EuroIntervention</i> , 2021, 17, 220-228.	3.2	6
34	High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial. <i>Circulation</i> , 2021, 143, 2214-2224.	1.6	80
35	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. <i>CJC Open</i> , 2021, 3, 1257-1272.	1.5	18
36	Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials. <i>Open Heart</i> , 2021, 8, e001633.	2.3	1

#	ARTICLE	IF	CITATIONS
37	What an Interventionalist Needs to Know About MI with Non-obstructive Coronary Arteries. <i>Interventional Cardiology Review</i> , 2021, 16, e10.	1.6	9
38	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1130.	6.1	114
39	Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial. <i>European Heart Journal</i> , 2021, 42, 3844-3852.	2.2	74
40	The role of a comprehensive two-step diagnostic evaluation to unravel the pathophysiology of MINOCA: A review. <i>International Journal of Cardiology</i> , 2021, 336, 1-7.	1.7	16
41	Use of High-Sensitivity Cardiac Troponin in Patients With Kidney Impairment. <i>JAMA Internal Medicine</i> , 2021, 181, 1237.	5.1	9
42	Neural network-based left ventricle geometry prediction from CMR images with application in biomechanics. <i>Artificial Intelligence in Medicine</i> , 2021, 119, 102140.	6.5	10
43	The Full Revasc (Ffr-guidance for complete non-culprit REVASCularization) Registry-based randomized clinical trial. <i>American Heart Journal</i> , 2021, 241, 92-100.	2.7	4
44	Risk Stratification Guided by the Index of Microcirculatory Resistance and Left Ventricular End-Diastolic Pressure in Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009529.	3.9	8
45	Myocardial changes on 3T cardiovascular magnetic resonance imaging in response to haemodialysis with fluid removal. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 125.	3.3	9
46	What an Interventionalist Needs to Know About INOCA. <i>Interventional Cardiology Review</i> , 2021, 16, e32.	1.6	3
47	The Future of Cardiac Magnetic Resonance Clinical Trials. <i>JACC: Cardiovascular Imaging</i> , 2021, , .	5.3	6
48	High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2020, 141, 161-171.	1.6	124
49	1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 33-45.	2.9	141
50	Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. <i>Cardiovascular Research</i> , 2020, 116, 787-805.	3.8	119
51	Human Microcirculation in Ischemic Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 11-13.	2.4	2
52	Fractional Flow Reserve Derived from Computed Tomography Coronary Angiography in the Assessment and Management of Stable Chest Pain: Rationale and Design of the FORECAST Trial. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 890-896.	0.8	13
53	Sex associations and computed tomography coronary angiography-guided management in patients with stable chest pain. <i>European Heart Journal</i> , 2020, 41, 1337-1345.	2.2	28
54	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study. <i>American Heart Journal</i> , 2020, 221, 48-59.	2.7	27

#	ARTICLE	IF	CITATIONS
55	Chronic infarct size after spontaneous coronary artery dissection: implications for pathophysiology and clinical management. <i>European Heart Journal</i> , 2020, 41, 2197-2205.	2.2	35
56	Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK. <i>Heart</i> , 2020, 106, 1890-1897.	2.9	90
57	Assessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1847-1864.	2.9	105
58	Bias and Loss to Follow-Up in Cardiovascular Randomized Trials: A Systematic Review. <i>Journal of the American Heart Association</i> , 2020, 9, e015361.	3.7	7
59	BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1149-1151.	3.6	83
60	Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial. <i>American Heart Journal</i> , 2020, 229, 70-80.	2.7	40
61	Chest pain without obstructive coronary artery disease: a case series. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.6	2
62	Cardiac Imaging in the Post-ISCHEMIA Trial Era. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1815-1833.	5.3	21
63	The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study. <i>Cardiovascular Research</i> , 2020, 116, 2185-2196.	3.8	31
64	Redefining Adverse and Reverse Left Ventricular Remodeling by Cardiovascular Magnetic Resonance Following ST-Segment Elevation Myocardial Infarction and Their Implications on Long-Term Prognosis. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009937.	2.6	24
65	Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal</i> , 2020, 41, 4092-4099.	2.2	174
66	Comparative Significance of Invasive Measures of Microvascular Injury in Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008505.	3.9	37
67	Coronary microvascular disease: the next frontier for Cardiovascular Research. <i>Cardiovascular Research</i> , 2020, 116, 737-740.	3.8	13
68	Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1406-1421.	2.8	16
69	A global registry of fractional flow reserve (FFR)-guided management during routine care: Study design, baseline characteristics and outcomes of invasive management. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E423-E431.	1.7	3
70	An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. <i>European Heart Journal</i> , 2020, 41, 3504-3520.	2.2	385
71	A randomized controlled trial of a physiology-guided percutaneous coronary intervention optimization strategy: Rationale and design of the TARGET FFR study. <i>Clinical Cardiology</i> , 2020, 43, 414-422.	1.8	13
72	Commentary - The ISCHEMIA trial. <i>International Journal of Cardiology</i> , 2020, 304, 1-4.	1.7	7

#	ARTICLE	IF	CITATIONS
73	One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008855.	3.9	5
74	Treatment of coronary microvascular dysfunction. <i>Cardiovascular Research</i> , 2020, 116, 856-870.	3.8	114
75	Angina: contemporary diagnosis and management. <i>Heart</i> , 2020, 106, 387-398.	2.9	29
76	Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. <i>European Heart Journal</i> , 2020, 41, 3239-3252.	2.2	73
77	Effects of Intracoronary Alteplase on Microvascular Function in Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e014066.	3.7	11
78	Immediate vs Delayed Stenting in ST-Elevation Myocardial Infarction: Rationale and Design of the International PRIMACY Bayesian Randomized Controlled Trial. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1805-1814.	1.7	10
79	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. <i>Cardiovascular Research</i> , 2020, 116, 1666-1687.	3.8	1,074
80	Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial. <i>Heart</i> , 2020, 106, 758-764.	2.9	13
81	Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. <i>BMJ Open</i> , 2020, 10, e040402.	1.9	108
82	International prospective cohort study of microvascular angina – Rationale and design. <i>IJC Heart and Vasculature</i> , 2020, 31, 100630.	1.1	6
83	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-86.	0.7	0
84	Redefining successful primary PCI. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 133-135.	1.2	18
85	Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 993-1003.	5.3	46
86	Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory. <i>Heart</i> , 2019, 105, 1536-1542.	2.9	53
87	Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2019, 74, 238-256.	2.8	235
88	Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007830.	3.9	17
89	Optimized Treatment of ST-Elevation Myocardial Infarction. <i>Circulation Research</i> , 2019, 125, 245-258.	4.5	140
90	Guiding Therapy by Coronary CT Angiography Improves Outcomes in Patients With Stable Chest Pain. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2058-2070.	2.8	99

#	ARTICLE	IF	CITATIONS
91	Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2032-2043.	2.8	84
92	“Acute micro-coronary syndrome”™: detailed coronary physiology in a patient with Takotsubo cardiomyopathy. <i>BMJ Case Reports</i> , 2019, 12, e229618.	0.5	5
93	High-Sensitivity Troponin and the Application of Risk Stratification Thresholds in Patients With Suspected Acute Coronary Syndrome. <i>Circulation</i> , 2019, 140, 1557-1568.	1.6	79
94	Toward Improving Our Understanding of the Relationship Between IMR and MVO in STEMI Patients. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1593-1594.	5.3	2
95	Predictors of segmental myocardial functional recovery in patients after an acute ST-Elevation myocardial infarction. <i>European Journal of Radiology</i> , 2019, 112, 121-129.	2.6	16
96	Predictive factors of discordance between the instantaneous wave-free ratio and fractional flow reserve. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 356-363.	1.7	49
97	Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease. <i>New England Journal of Medicine</i> , 2019, 380, 2418-2428.	27.0	326
98	Conversation in cardiology: Is there a need for clinical trials for the nonhyperemic pressure ratios?. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 227-232.	1.7	4
99	How to Diagnose and Manage Angina Without Obstructive Coronary Artery Disease: Lessons from the British Heart Foundation CorMicA Trial. <i>Interventional Cardiology Review</i> , 2019, 14, 76-82.	1.6	50
100	Sex-based associations with microvascular injury and outcomes after ST-segment elevation myocardial infarction. <i>Open Heart</i> , 2019, 6, e000979.	2.3	7
101	Fibrinolytic Therapy to Reduce Microvascular Obstruction After Myocardial Infarction—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2033.	7.4	0
102	Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1171-1181.	3.4	31
103	Targeting an Ischemic Time <120 Minutes in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2019, 8, e013067.	3.7	4
104	The Potential Use of the Index of Microcirculatory Resistance to Guide Stratification of Patients for Adjunctive Therapy in Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 951-966.	2.9	25
105	Cardiovascular health technology assessment: recommendations to improve the quality of evidence. <i>Open Heart</i> , 2019, 6, e000930.	2.3	1
106	Treating Multivessel Coronary Artery Disease in ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 731-733.	2.9	0
107	Diastolic pressure ratio: new approach and validation vs. the instantaneous wave-free ratio. <i>European Heart Journal</i> , 2019, 40, 2585-2594.	2.2	44
108	Feature-tracking myocardial strain in healthy adults- a magnetic resonance study at 3.0 tesla. <i>Scientific Reports</i> , 2019, 9, 3239.	3.3	37

#	ARTICLE	IF	CITATIONS
109	Smallâ€Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions. <i>Journal of the American Heart Association</i> , 2019, 8, e011104.	3.7	71
110	Post-operative myocardial infarction following aortic root surgery with coronary reimplantation: a case series treated with percutaneous coronary intervention. <i>European Heart Journal - Case Reports</i> , 2019, 3, 1-6.	0.6	4
111	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 2497-2505.	27.0	1,696
112	Ischemia and No Obstructive Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008126.	3.9	107
113	Circumferential Strain Predicts Major Adverse Cardiovascular Events Following an Acute ST-Segmentâ€Elevation Myocardial Infarction. <i>Radiology</i> , 2019, 290, 329-337.	7.3	32
114	Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. <i>European Heart Journal</i> , 2019, 40, 2455-2462.	2.2	85
115	Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 56.	7.4	88
116	Contrast fractional flow reserve: Attractive alternative to non-hyperaemic pressure ratios for coronary disease evaluation. <i>International Journal of Cardiology</i> , 2019, 275, 46-47.	1.7	0
117	Failed myocardial reperfusion during primary PCI: an unmet therapeutic need. <i>EuroIntervention</i> , 2019, 14, 1628-1630.	3.2	4
118	Stable Coronary Syndromes. , 2019, , 373-381.		0
119	High-Sensitivity Cardiac Troponin I and the Diagnosis of Coronary Artery Disease in Patients With Suspected Angina Pectoris. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004227.	2.2	41
120	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. <i>American Heart Journal</i> , 2018, 201, 86-94.	2.7	22
121	Coronary microvascular dysfunction in patients with stable coronary artery disease: The CE-MARC 2 coronary physiology sub-study. <i>International Journal of Cardiology</i> , 2018, 266, 7-14.	1.7	41
122	Cardiovascular Magnetic Resonance in Acute ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation</i> , 2018, 137, 1949-1964.	1.6	128
123	How to Mend a Broken Heart?. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 420-422.	5.3	0
124	Diagnostic and prognostic benefits of computed tomography coronary angiography using the 2016 National Institute for Health and Care Excellence guidance within a randomised trial. <i>Heart</i> , 2018, 104, 207-214.	2.9	41
125	Persistent Iron Within the Infarct Coreâ€After ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1248-1256.	5.3	43
126	Reference invasive tests of microvascular injury in myocardial infarction. <i>Heart</i> , 2018, 104, 90-92.	2.9	3

#	ARTICLE	IF	CITATIONS
127	Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study. <i>Open Heart</i> , 2018, 5, e000924.	2.3	12
128	Systemic microvascular dysfunction in microvascular and vasospastic angina. <i>European Heart Journal</i> , 2018, 39, 4086-4097.	2.2	139
129	Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 67.	3.3	101
130	Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2841-2855.	2.8	436
131	Coronary Thrombolysis Waveforms After Acute Reperfusion ST-segment Elevation Myocardial Infarction: Relation to Microvascular Obstruction and Prognosis. <i>Journal of the American Heart Association</i> , 2018, 7, e008957.	3.7	5
132	Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1321-1329.	2.8	40
133	Sex Differences in Adenosine-Free Coronary Pressure Indexes. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1454-1463.	2.9	12
134	Prevention of Coronary Microvascular Obstruction by Addressing Distal Embolization. , 2018, , 237-253.		0
135	Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction. <i>Hypertension</i> , 2018, 72, 720-730.	2.7	33
136	Strategies in Stable Chronic Coronary Disease. , 2018, , 901-919.		0
137	Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2018, 379, 924-933.	27.0	898
138	High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. <i>Lancet</i> , 2018, 392, 919-928.	13.7	263
139	Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. <i>Heart</i> , 2018, 104, 284-292.	2.9	86
140	Validation of a novel non-hyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study. <i>EuroIntervention</i> , 2018, 14, 806-814.	3.2	157
141	Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial. <i>Heart</i> , 2017, 103, 995-1001.	2.9	40
142	Meta-Analysis of the Index of Microvascular Resistance in Acute STEMI Using Incomplete Data. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 421-422.	2.9	1
143	Validation of the "smart" minimum FFR Algorithm in an unselected all comer population of patients with intermediate coronary stenoses. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 991-997.	1.5	3
144	Fractional flow reserve: a clinical perspective. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 961-974.	1.5	19

#	ARTICLE	IF	CITATIONS
145	Diagnostic Accuracy of 3.0-T Magnetic Resonance T1 and T2 Mapping and T2-Weighted Dark-Blood Imaging for the Infarct-Related Coronary Artery in Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	15
146	Myocardial changes in incident haemodialysis patients over 6-months: an observational cardiac magnetic resonance imaging study. <i>Scientific Reports</i> , 2017, 7, 13976.	3.3	6
147	Meta-Analysis of Death and Myocardial Infarction in the DEFINE-FLAIR and iFR-SWEDEHEART Trials. <i>Circulation</i> , 2017, 136, 2389-2391.	1.6	32
148	Agreement of the Resting Distal to Aortic Coronary Pressure With the Instantaneous Wave-Free Ratio. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2105-2113.	2.8	43
149	Influence of Contrast Media Dose and Osmolality on the Diagnostic Performance of Contrast Fractional Flow Reserve. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	8
150	Estimating prognosis in patients with acute myocardial infarction using personalized computational heart models. <i>Scientific Reports</i> , 2017, 7, 13527.	3.3	22
151	Aortic Wall Inflammation Predicts Abdominal Aortic Aneurysm Expansion, Rupture, and Need for Surgical Repair. <i>Circulation</i> , 2017, 136, 787-797.	1.6	122
152	Changes and classification in myocardial contractile function in the left ventricle following acute myocardial infarction. <i>Journal of the Royal Society Interface</i> , 2017, 14, 20170203.	3.4	50
153	Persistence of Infarct Zone T2 Hyperintensity at 6 Months After Acute ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	16
154	Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial. <i>European Radiology</i> , 2017, 27, 2957-2968.	4.5	33
155	Comparison of Different Diastolic Resting Indexes to iFR. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3088-3096.	2.8	163
156	Cardiovascular Diagnosis and Therapy (CDT) Editorial: the Minimalist Immediate Mechanical Intervention study. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, S73-S76.	1.7	0
157	Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome. <i>PLoS ONE</i> , 2017, 12, e0168448.	2.5	13
158	Infarct size and left ventricular remodelling after preventive percutaneous coronary intervention. <i>Heart</i> , 2016, 102, 1980-1987.	2.9	11
159	Remote Zone Extracellular Volume and Left Ventricular Remodeling in Survivors of ST-Elevation Myocardial Infarction. <i>Hypertension</i> , 2016, 68, 385-391.	2.7	44
160	Impact of Incomplete Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	36
161	New perspectives on the role of cardiac magnetic resonance imaging to evaluate myocardial salvage and myocardial hemorrhage after acute reperfused ST-elevation myocardial infarction. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 843-854.	1.5	14
162	Temporal Evolution of Myocardial Hemorrhage and Edema in Patients After Acute ST-Segment Elevation Myocardial Infarction: Pathophysiological Insights and Clinical Implications. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	96

#	ARTICLE	IF	CITATIONS
163	“Waves of Edema” Seem Implausible. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1868-1869.	2.8	5
164	Use of Coronary Computed Tomographic Angiography to Guide Management of Patients With Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1759-1768.	2.8	274
165	Continuum of Vasodilator Stress From Rest to Contrast Medium to Adenosine Hyperemia for Fractional Flow Reserve Assessment. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 757-767.	2.9	129
166	Risk assessment in patients with an acute ST-elevation myocardial infarction. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 581-593.	1.4	8
167	Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping. <i>Kidney International</i> , 2016, 90, 845-852.	5.2	88
168	Advances in Magnetic Resonance Imaging of the Myocardial Area at Risk and Salvage. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	2.6	3
169	Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1051.	7.4	227
170	Discordance Between Resting and Hyperemic Indices of Coronary Stenosis Severity. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	67
171	The Influence of Lesion Location on the Diagnostic Accuracy of Adenosine-Free Coronary Pressure Wire Measurements. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2390-2399.	2.9	81
172	Comparative Prognostic Utility of Indexes of Microvascular Function Alone or in Combination in Patients With an Acute ST-Segment “Elevation Myocardial Infarction. <i>Circulation</i> , 2016, 134, 1833-1847.	1.6	135
173	Myocardial Hemorrhage After Acute Reperused ST-Segment “Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004148.	2.6	158
174	Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperused ST-elevation myocardial infarction survivors. <i>European Heart Journal</i> , 2016, 37, 1044-1059.	2.2	105
175	Native myocardial longitudinal ( $T_{1\rho}$ ) relaxation time: Regional, age, and sex associations in the healthy adult heart. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 541-548.	3.4	62
176	Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. <i>International Journal of Cardiology</i> , 2016, 202, 305-310.	1.7	20
177	Native T1 mapping: inter-study, inter-observer and inter-center reproducibility in hemodialysis patients. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 19, 21.	3.3	50
178	Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. <i>JCI Insight</i> , 2016, 1, e85768.	5.0	39
179	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 19.	1.5	14
180	Physiological assessment of coronary lesion severity. <i>Coronary Artery Disease</i> , 2015, 26, e8-e14.	0.7	2

#	ARTICLE	IF	CITATIONS
181	Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments. <i>European Heart Journal</i> , 2015, 36, 3155-3164.	2.2	58
182	MRI using ultrasmall superparamagnetic particles of iron oxide in patients under surveillance for abdominal aortic aneurysms to predict rupture or surgical repair: MRI for abdominal aortic aneurysms to predict rupture or surgery—the MA <sup>3</sup> RS study. <i>Open Heart</i> , 2015, 2, e000190.	2.3	41
183	Observer variability in the assessment of CT coronary angiography and coronary artery calcium score: substudy of the Scottish COmputed Tomography of the HEART (SCOT-HEART) trial. <i>Open Heart</i> , 2015, 2, e000234.	2.3	35
184	Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE-MARC 2): A prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease. <i>American Heart Journal</i> , 2015, 169, 17-24.e1.	2.7	25
185	Invasive assessment of the coronary microcirculation in the catheter laboratory. <i>International Journal of Cardiology</i> , 2015, 199, 141-149.	1.7	12
186	Pathophysiology of LV Remodeling in Survivors of STEMI. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 779-789.	5.3	116
187	Repeatability of Fractional Flow Reserve Despite Variations in Systemic and Coronary Hemodynamics. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1018-1027.	2.9	83
188	Current frontiers in the clinical research of coronary physiology. <i>Interventional Cardiology</i> , 2015, 7, 97-108.	0.0	0
189	Intracoronary Adenosine for Maximal Hyperemia. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1431-1432.	2.9	1
190	Assessment of the relationships between myocardial contractility and infarct tissue revealed by serial magnetic resonance imaging in patients with acute myocardial infarction. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 1201-1209.	1.5	23
191	Assessment of Fractional Flow Reserve in Patients With Recent Non-ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002207.	3.9	17
192	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. <i>European Heart Journal</i> , 2015, 36, 100-111.	2.2	241
193	Is Hyperaemia Essential for Accurate Functional Assessment of Coronary Stenosis Severity?. <i>Interventional Cardiology Review</i> , 2015, 10, 72.	1.6	0
194	Response to Letter Regarding Article, “Prognostic Value of the Index of Microcirculatory Resistance Measured After Primary Percutaneous Coronary Intervention”. <i>Circulation</i> , 2014, 129, e342.	1.6	0
195	Effects of Neutral Endopeptidase (Nepriylsin) Inhibition on the Response to Other Vasoactive Peptides in Small Human Resistance Arteries: Studies with Thiorphan and Omapatrilat. <i>Cardiovascular Therapeutics</i> , 2014, 32, 13-18.	2.5	38
196	TGF- $\beta$ 2 Signaling Mediates Endothelial-to-Mesenchymal Transition (EndMT) During Vein Graft Remodeling. <i>Science Translational Medicine</i> , 2014, 6, 227ra34.	12.4	321
197	LGE and NT-proBNP Identify Low Risk of Death or Arrhythmic Events in Patients With Primary Prevention ICDs. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 561-569.	5.3	26
198	A Randomized Trial of Deferred Stenting Versus Immediate Stenting to Prevent No- or Slow-Reflow in Acute ST-Segment Elevation Myocardial Infarction (DEFER-STEMI). <i>Journal of the American College of Cardiology</i> , 2014, 63, 2088-2098.	2.8	204

#	ARTICLE	IF	CITATIONS
199	Adenosine. JACC: Cardiovascular Interventions, 2014, 7, 581-591.	2.9	214
200	Multicenter Core Laboratory Comparison of the Instantaneous Wave-Free Ratio and Resting P /P With Fractional Flow Reserve. Journal of the American College of Cardiology, 2014, 63, 1253-1261.	2.8	301
201	Left ventricular strain and its pattern estimated from cine CMR and validation with DENSE. Physics in Medicine and Biology, 2014, 59, 3637-3656.	3.0	31
202	Comprehensive Dobutamine Stress CMR Versus Echocardiography in LBBB and Suspected Coronary Artery Disease. JACC: Cardiovascular Imaging, 2014, 7, 490-498.	5.3	30
203	VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment) Tj ETQq1 1 0.784314 rgBT /Ove Cardiology, 2013, 61, 1421-1427.	2.8	197
204	Randomized Trial of Preventive Angioplasty in Myocardial Infarction. New England Journal of Medicine, 2013, 369, 1115-1123.	27.0	871
205	Highly automatic quantification of myocardial oedema in patients with acute myocardial infarction using bright blood T2-weighted CMR. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 28.	3.3	10
206	Fractional flow reserve versus angiography in guiding management to optimize outcomes in nonâ€“ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial. American Heart Journal, 2013, 166, 662-668.e3.	2.7	11
207	Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC metaâ€“analysis report. European Journal of Heart Failure, 2013, 15, 1220-1227.	7.1	28
208	The Role of Cardiac Magnetic Resonance Imaging (MRI) in Acute Myocardial Infarction (AMI). Heart Lung and Circulation, 2013, 22, 243-255.	0.4	31
209	Usefulness of Fractional Flow Reserve to Improve Diagnostic Efficiency in Patients With Non-ST Elevation Myocardial Infarction. American Journal of Cardiology, 2013, 111, 45-50.	1.6	21
210	Prognostic importance of myocardial infarct characteristics. European Heart Journal Cardiovascular Imaging, 2013, 14, 313-315.	1.2	13
211	Vasodilatory Capacity of the Coronary Microcirculation is Preserved in Selected Patients With Nonâ€“ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2013, 6, 231-236.	3.9	103
212	Prognostic Importance of a New Measure of Global Systolic Heart Function in Healthy Adults. Hypertension, 2013, 61, 762-764.	2.7	3
213	Prognostic Value of the Index of Microcirculatory Resistance Measured After Primary Percutaneous Coronary Intervention. Circulation, 2013, 127, 2436-2441.	1.6	316
214	Microvascular Resistance Predicts Myocardial Salvage and Infarct Characteristics in STâ€“Elevation Myocardial Infarction. Journal of the American Heart Association, 2012, 1, e002246.	3.7	80
215	Clinical outcomes following radial versus femoral artery access in primary or rescue percutaneous coronary intervention in Scotland: retrospective cohort study of 4534 patients. Heart, 2012, 98, 552-557.	2.9	45
216	Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient metaâ€“analysisâ€“. European Journal of Heart Failure, 2012, 14, 473-479.	7.1	167

#	ARTICLE	IF	CITATIONS
217	Role of multidetector computed tomography in the diagnosis and management of patients attending the rapid access chest pain clinic, The Scottish computed tomography of the heart (SCOT-HEART) trial: study protocol for randomized controlled trial. <i>Trials</i> , 2012, 13, 184.	1.6	52
218	Bright-Blood T <sub>2</sub> -Weighted MRI Has High Diagnostic Accuracy for Myocardial Hemorrhage in Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 738-745.	2.6	57
219	Bright-Blood T <sub>2</sub> -Weighted MRI Has Higher Diagnostic Accuracy Than Dark-Blood Short Tau Inversion Recovery MRI for Detection of Acute Myocardial Infarction and for Assessment of the Ischemic Area at Risk and Myocardial Salvage. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 210-219.	2.6	99
220	The Index of Microcirculatory Resistance Measured Acutely Predicts the Extent and Severity of Myocardial Infarction in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 715-722.	2.9	161
221	Magnetic Resonance Imaging Delineates the Ischemic Area at Risk and Myocardial Salvage in Patients With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 527-535.	2.6	114
222	Remodeling is a more important determinant of lumen size than atheroma burden in left main coronary artery disease. <i>American Heart Journal</i> , 2010, 160, 188-194.e1.	2.7	6
223	The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. <i>European Journal of Heart Failure</i> , 2009, 11, 855-862.	7.1	114
224	Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes. <i>Current Atherosclerosis Reports</i> , 2008, 10, 106-116.	4.8	3
225	Role of Transesophageal Echocardiography in Percutaneous Aortic Valve Replacement with the CoreValve Revalving System. <i>Echocardiography</i> , 2008, 25, 840-848.	0.9	37
226	Cardiac magnetic resonance findings predict increased resource utilization in elective coronary artery bypass grafting. <i>Clinical Science</i> , 2008, 114, 423-430.	4.3	3
227	Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1675.	7.4	652
228	Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. <i>European Journal of Heart Failure</i> , 2007, 9, 429-434.	7.1	50
229	Importance of collateral circulation in coronary heart disease. <i>European Heart Journal</i> , 2007, 28, 278-291.	2.2	118
230	Implantation of the CoreValve Percutaneous Aortic Valve. <i>Annals of Thoracic Surgery</i> , 2007, 83, 284-287.	1.3	20
231	Coronary Heart Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2007, 49, 631-642.	2.8	132
232	Corrigendum to "Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker" [European Journal of Heart Failure 9/4 (2007) 429-434]. <i>European Journal of Heart Failure</i> , 2007, 9, 1074-1074.	7.1	0
233	Fatal ischemic stroke related to nonpermissive peripheral artery access for percutaneous aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 56-63.	1.7	38
234	Management of a spontaneous renal capsule hematoma following cardiac catheterization involving use of a platelet glycoprotein IIb/IIIa inhibitor: A case report. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 994-997.	1.7	2

#	ARTICLE	IF	CITATIONS
235	Novel therapeutic aspects of percutaneous aortic valve replacement with the 21F CoreValve Revalvingâ„¢ System. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 610-616.	1.7	53
236	Surgical aspects of endovascular retrograde implantation of the aortic CoreValve bioprosthesis in high-risk older patients with severe symptomatic aortic stenosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 134, 1150-1156.	0.8	58
237	The prevalence, nature, and importance of hematologic abnormalities in heart failure. <i>American Heart Journal</i> , 2006, 151, 1313-1321.	2.7	54
238	Transcatheter closure of a ventricular septal defect resulting from knife stabbing using the Amplatzer muscular VSD occluder. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 153-156.	1.7	16
239	First case of combined percutaneous aortic valve replacement and coronary artery revascularisation. <i>EuroIntervention</i> , 2006, 2, 257-61.	3.2	8
240	Ximelagatran Compared with Warfarin for the Prevention of Systemic Embolism and Stroke. An Imputed Placebo Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 149-151.	2.6	2
241	Comparison of femoral bleeding complications after coronary angiography versus percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2004, 94, 361-363.	1.6	65
242	Telephone follow-up by nurses reduces hospital readmissions among people with chronic heart failure. <i>Evidence-Based Healthcare and Public Health</i> , 2002, 6, 152-153.	0.0	2
243	Oxidative stress and vascular damage in hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 247-255.	2.0	123
244	Economics of chronic heart failure. <i>European Journal of Heart Failure</i> , 2001, 3, 283-291.	7.1	315
245	Effects of Urotensin II in Human Arteries and Veins of Varying Caliber. <i>Circulation</i> , 2001, 103, 1378-1381.	1.6	87
246	Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. <i>Heart</i> , 2001, 86, 217-220.	2.9	0
247	Investigation Into the Sources of Superoxide in Human Blood Vessels. <i>Circulation</i> , 2000, 101, 2206-2212.	1.6	287
248	Coronary Heart Disease and Diabetes. , 0, , 37-67.		0
249	Diabetes and Acute Coronary Syndromes. , 0, , 69-92.		0